Quick Market Round-up before the Bell: Delcath Systems, Valeant Pharma Intl., BioMarin Pharma, and Insmed Editor Note: For more information about this release, please scroll to bottom PR Newswire LONDON, January 9, 2014 LONDON, January 9, 2014 /PRNewswire/ -- On Wednesday, January 08, 2014, the US equity market ended on a mixed note. The S&P 500 ended the day 0.02% lower at 1,837.49; the Dow Jones Industrial Average finished 0.41% lower at 16,462.74; and the NASDAQ Composite closed 0.30% higher at 4,165.61. The S&P 500 Health Care Sector Index edged 0.88% higher to end the day at 649.79; and the same has gained 1.89% in the last one month and 12.44% in the previous three months, outperforming the S&P 500, which has advanced 1.79% and 11.00% during the respective periods. The major movers in the Health Care sector included Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Insmed Inc. (NASDAQ: INSM). AAAResearchReports.com has released full comprehensive research on DCTH, VRX, BMRN, and INSM. These free technical analyses can be downloaded by signing up at: http://www.aaaresearchreports.com/register/ Delcath Systems Inc.'s stock ended flat on Wednesday, closing the day at the previous day's closing price of $0.28, after fluctuating between $0.27 and $0.29. A total of 4.28 million shares were traded, which is above the daily average volume of 2.05 million. The company's shares have fallen by 36.82% in the previous three months, underperforming the S&P 500, which has gained 11.00% during the same period. Moreover, Delcath Systems Inc.'s stock is below its 50-day and 200-day moving averages of $0.29 and $0.52, respectively. A free technical analysis on DCTH available by signing up at: http://www.AAAResearchReports.com/DCTH010914.pdf On Wednesday, shares in Valeant Pharmaceuticals Intl. Inc. closed the day at $128.30, which is 2.35% higher than the previous day's closing price of $125.35. The company's shares vacillated between $126.55 and $135.73 during the trading session. A total of 3.03 million shares were traded, which is above the daily average volume of 1.12 million. The company's shares have surged 19.16% in the last one month and 21.13% in the previous three months, outperforming the S&P 500, which has advanced 1.79% and 11.00% during the respective periods. Additionally, Valeant Pharmaceuticals Intl. Inc.'s stock is trading above its 50-day and 200-day moving averages of $109.86 and $95.30, respectively. Register today and access free research on VRX at: http://www.AAAResearchReports.com/VRX010914.pdf Shares in BioMarin Pharmaceutical Inc. gained 1.82% on Wednesday, finishing the day at $69.79. The company's shares fluctuated between $67.52 and $69.90 during the trading session. A total of 0.75 million shares were traded, which is below the daily average volume of 1.55 million. The company's shares have advanced 1.01% in the previous three trading sessions and 3.78% in the last three months, compared to a gain of 0.33% and 11.00% in the S&P 500 during the respective periods. Furthermore, BioMarin Pharmaceutical Inc.'s stock is trading above its 50-day and 200-day moving averages of $67.47 and $65.49, respectively. The free report on BMRN can be downloaded by signing up now at: http://www.AAAResearchReports.com/BMRN010914.pdf On Wednesday, Insmed Inc.'s stock oscillated between $18.00 and $18.63, hitting a new 52-week high of $18.63. The company's shares ended the day 2.73% higher at $18.47. A total of 0.38 million shares were traded, which is below the daily average volume of 0.49 million. The company's shares have surged 11.60% in the last one month and 33.17% in the previous three months, outperforming the S&P 500, which has advanced 1.79% and 11.00% during the respective periods. Further, Insmed Inc.'s stock is trading above its 50-day and 200-day moving averages of $15.80 and $12.74, respectively. A free report on INSM can be accessed by registering at: http://www.AAAResearchReports.com/INSM010914.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID: email@example.com
Quick Market Round-up before the Bell: Delcath Systems, Valeant Pharma Intl., BioMarin Pharma, and Insmed
Press spacebar to pause and continue. Press esc to stop.